A Potential New Mouse Model of Axial Spondyloarthritis Involving the Complement System

V. Michael Holers, Francisco G. La Rosa, Nirmal K. Banda

ABSTRACT

Many mouse models of rheumatoid arthritis have been identified, but only a limited number are present for axial spondyloarthritis (AxSpA). Collagen Ab-induced arthritis (CAIA) is one of the most widely used mouse models of arthritis, and it is complement-dependent. We found that mice developing CAIA also developed spinal lesions similar to those found in AxSpA. To induce CAIA, mice were injected intraperitoneally at day 0 with anti-collagen Abs, followed by LPS injection at day 3. CAIA mice demonstrated a significant kyphosis through the spine, as well as hypertrophic cartilage and osseous damage of the intravertebral joints. Immunohistochemical staining of the kyphotic area revealed increased complement C3 deposition and macrophage infiltration, with localization to the intravertebral joint margins. Near Infrared (NIR) in vivo imaging showed that anti-collagen Abs conjugated with IRDye® 800CW not only localized to cartilage surface in the joints but also to the spine in arthritic mice. We report here a novel preclinical mouse model in which, associated with the induction of CAIA, mice also exhibited salient features of AxSpA; this new experimental model of AxSpA may allow investigators to shed light on the local causal mechanisms of AxSpA bone and soft tissue changes as well as treatment.

Keywords: Axial spondyloarthritis; Arthritis; Complement

INTRODUCTION

Spondyloarthritis (SpA) represents a group of inflammatory diseases that are characterized by inflammation and tissue damage within the spine, sacro-iliac joints and/or peripheral joints. Axial spondyloarthritis (AxSpA) involve spine but not peripheral joints. Overall, SpA has been classified into various categories such as ankylosing spondylitis (AS), AxSpA, psoriatic arthritis, reactive arthritis (RA), and enteropathic arthritis (ulcerative colitis and Crohn’s disease). AS is the most common SpA, and its prevalence in the US has been estimated to be 0.2% to 0.5% (1). AS is characterized by inflammation at the entheses that is followed by osteoproliferation, or new bone formation, which often leads to fusion (ankylosis) of the affected joints. HLA-B27 is the major Class I gene associated with AS, as about 90% of patients express this allele (2).
There are 2 types of AxSpA; one is radiographic and second is non-radiographic and subjects with AxSpA can have inflammation in non-articular sites. With regard to animal models, it has been shown in HLA-B27 rats with overexpression of human β2-microglobulin that these animals developed the clinical (arthritis and dactylitis) and histopathologic features (synovitis, spondylitis, enthesitis, fibrosis, and bony proliferation) of the arthritic disease resemble human SpA to a greater degree than has been observed in the high-copy HLA-B27/Huβ2m (3). It has also been shown that older male DBA/1 mice develop spontaneous enthesal cell proliferation and infiltration, progressively leading to endochondral bone formation similar to human SpA (4). By using HLA-B27 transgenic mice, it has been shown that there is an increased inflammation in the collagen Ab-induced arthritis (CAIA) model, but there was no effect on bone formation in AxSpA (5); in this later study no analysis of spine tissue was reported. With regard to mechanism, recently it has been shown by using mesenchymal stem cells from AS patients that HLA-B27 misfolding activates a p-IRE1/sXBP1/RARB/TNAP pathway which contributes to the pathogenesis of bone mineralization and ectopic bone formation at inflamed entheses (6). Interestingly despite of strong association of HLA-B27 with AS, initial studies with HLA-B27 expressed in mice lacking β2m were not reproducible (7,8) and it was shown that the frequency of spontaneous inflammatory arthritis was not increased by HLA-B27 in β2m B6 mice (8).

Previously, SpA was normally considered an auto-inflammatory disease, but this view is evolving due in part to the reported presence of autoantibodies in a subset of SpA patients (9). In addition, studies have shown that Th17 cells might be involved in the pathogenesis of SpA (10). Targeted liver overexpression of IL-23 in B10.RIII resulted in an AxSpA phenotype as well as peripheral disease that was due to the activation of enthesal-resident non-canonical T cells (5). Nonetheless, the presence of autoantibodies is the main characteristic of autoimmune disease, and sometime these autoantibodies are even present before the development of disease. For example, anti-β2m Abs have been reported in SpA patients (11).

Some reports also suggest the presence of anti-type I and type II collagen Abs in SpA patients (12). In one study, serum levels of metalloproteinase-degraded collagen type I (C1M), type II (C2M), type III (C3M) and type IV (C4M2) were quantified (13). These investigators found that the best metabolite that differentiates between AxSpA and control was C3M, i.e., type III (13). Overall this study suggested that collagen degradation metabolites are higher in AxSpA and these metabolites may be disease activity biomarkers of AxSpA. In another study, Abs against collagen were analyzed and found that AS patients exhibited slightly increased levels as compared to controls (14). Thus, collagen and reactivity to it as an integral part of the cartilage might play an important role in the pathogenesis of SpA.

Our previously studies showed the important role complement system in CAIA in mice (15). The complement system is one of the major effector arms of the innate immunity and is activated by 3 different pathways, i.e., classical, lectin pathway and alternative pathway. Regardless of how these 3 pathways get activated, all of these pathways converge to cleave C3. An activated complement system generates effectors such as anaphylatoxins (C3a, C5a), opsonins (C3b, iC3b, C3d) and membrane attack complex (MAC, C5b-9) (16). Furthermore, complement activation is linked to the adaptive immune responses. One of the most important functions of the complement system is the clearance of immune complexes and injured cells as well as serving as opsonins to clear the immune complexes and other debris (16). In vitro, adherent immune complexes of collagen and anti-collagen Abs activate C3 in normal serum but not in C3 complement deficient mice (17). Anti-collagen Abs
directly binds to the cartilage surface to form immune complexes (18) which can activate the complement. Anti-CD74 autoantibodies are found in early and late AxSpA patients (19) but their relationship to complement activation is not known. Interestingly although there are not many studies related to the role of complement in the pathogenesis of AxSpA, it has been shown that there is complement activation in AS and elevated complement proteins such as C3, C3d and C4 are found (20-22). Additionally, inhibition of complement retards the development of an AS model (23).

There exist various mouse and rat models of SpA, but these models might not fully mirror the human disease. Regardless, these models provide opportunities to examine the localized pathobiology of this disorder. SpA mouse models include the proteoglycan (24)-induced AS (25,26) and HLA-B27/human β2-microglobulin-transgenic model, which develop a multisystem disorder also involving spondylitis (27). HLA-B27 transgenic mice (28) and mice deficient in β2-microglobulin develop peripheral arthritis (29). An intraperitoneal injection of Curdlan resulted in the induction of SpA-like phenotype in the SKG mouse (30).

Here we report a potential new preclinical mouse model of AxSpA as a by-product of CAIA induction, which involves the complement system. Our results also suggest that one autoimmune disease, such as inflammatory arthritis, may also lead to a secondary autoimmune disease such as AxSpA; this interesting disease association may be due to the presence of anti-CII autoantibodies, or to some alteration of the immune system that requires further investigation. The main purpose of this publication is to report our unique observation on the effect of CAIA on the spine, leading to lesions similar to AxSpA and involvement of the complement system.

**MATERIALS AND METHODS**

**Combined CAIA and AxSpA induction**

A severe arthritis was induced in 6 week old C57BL/6 wild type (WT) mice (The Jackson Laboratory, Bar Harbor, ME, USA), by injecting a mixture of 5 anti-collagen monoclonal (anti-CII mAbs) (8 mg/mouse/i.p.) followed by an injection of LPS (50 ug/mouse/i.p.) (Escherichia coli strain) (17). Clinical disease activity (CDA) (31) in the joints in all mice was examined blindly from day 4 to day 10 according to our published studies (17). Briefly a 3-point scale was used for each paw: 0=normal joint; 1=slight inflammation and redness; 2=severe erythema and swelling affecting the entire paw; and 3=deformed paw or joint with ankylosis, joint rigidity, and loss of function (17,32). The maximum score of twelve per animal was based on the total score for all 4 paws, i.e., 3 for each paw. We also examined all mice for the presence of bending of the spine (kyphosis) from day 4 to day 10. All mice were sacrificed at day 10. All of these studies were approved by the Institutional Animal Care and Use Committee at the University of Colorado, Anschutz Medical Campus and all guidelines handling laboratory animals have been followed (No. B-14912(11)1E).

**Histopathology of AxSpA spine**

At day 10, the spine was surgically removed from sacrificed mice and fixed in a 10% neutral buffered formalin and processed for histopathology (17,32). Spine sections were also examined for inflammation, intervertebral disc (IVD) damage, cartilage damage, bone erosion, excess tissue formation and ectopic chondrocyte according to previously published criteria for a mouse model of AS (33). H&E staining was done to show histopathological
changes in the spine lesion area. Toluidine blue (T-blue) staining was used to examine the proliferation of chondrocytes in the deformed areas on the spine.

**Immunohistochemistry (IHC) for C3 fragment deposition and macrophages infiltration in the AxSpA mice spine**

At day 10, all specimens were evaluated with IHC staining using a polyclonal goat anti-mouse C3 antisera (34); C3 deposition was assessed in the spine kyphotic and surrounding area. Similarly, the presence of macrophages were also examined in the same areas of consecutive sections by using rat anti-mouse F4/80 Ab (34).

**In vivo imaging of arthritis joints and AxSpA spine using infrared IRDye800 dye**

For in vivo imaging, and to localize the anti-CII mAbs, WT mice were injected i.p. at day 0 with anti-CII mAbs conjugated with IRDye® 800CW (50 μg/mouse; LI-COR, Lincoln, NE, USA) (18). Anti-CII mAbs or control murine IgG were labelled with IRDye800 similarly (1–2 dye molecules/IgG). At day 14, mice were sacrificed for in vivo imaging to localize the IRDye800-conjugated anti-CII mAbs or control mIgG IRDye800-conjugated in the entire spine and also in the joints. Mice were scanned using LI-COR Odyssey Imaging system (LI-COR) according to our previous report (18).

**Statistics**

To assess the significant differences between means of mice with and without AxSpA for parameters such as C3, T-blue and histopathology, the Student’s t-test was used. The p<0.05 considered significant. Similarly, arthritis development in mice with AxSpA was compared with control mice using Student’s t-test (data not shown). All data were analyzed and graphs were plotted using statistical GraphPad Prism version 4.0 software (GraphPad, La Jolla, CA, USA).

**RESULTS**

**Co-development of arthritis and AxSpA in mice**

All mice with CAIA not only developed synovitis in the joints after 5–7 days, but also developed kyphosis consistent with AxSpA-like phenotype, whereas control mice did not (Fig. 1). The CDA in arthritis mice injected which also developed AxSpA was significantly high (p<0.05) 10.4±1.60 compared with the control mice (Fig. 1A). There was a significant (p<0.05) percent weight loss at day 10 in mice with CAIA/AxSpA (90.19±1.62) compared with mice without CAIA/AxSpA (105.93±3.02) (Fig. 1B).

In another cohort of WT mice (male or female) with arthritis consistently developed the AxSpA-like phenotype and there was a change in posture due to kyphosis however in mice without arthritis there was no change in the posture or AxSpA-like phenotype developed (Fig. 1C and D). At day 10, kyphosis in the spine was visible in mice with arthritis/AxSpA (Fig. 1C) but not in mice without arthritis/AxSpA (Fig. 1D). Furthermore, the kyphotic spine was clearly visible after making an incision on the skin above area with kyphosis (Fig. 1E and F). Autopsy examination at day 10 confirmed, after surgical exposure of the dorsal skin in the kyphotic area, that the spine was deformed showing kyphosis only in mice with arthritis injected with anti-CII Abs plus LPS but not in control mice (Fig. 1G and H).

**Histology of the kyphotic spine area of AxSpA mice**

At day 10, T-blue and also H&E staining showed that the majority of the mice with CAIA/AxSpA demonstrated chondrocyte proliferation in the kyphotic area (Fig. 2A) in contrast to the
control mice (Fig. 2B). Histopathology scores for inflammation (p<0.001), IVD destruction (p<0.05), cartilage damage (p<0.05), bone erosion (p<0.05), excess tissue formation (p<0.05) and presence of ectopic chondrocyte (p<0.007) all show a significant increase in mice with CAIA-AxSpA with kyphosis which was not seen in control mice with no kyphosis (Fig. 2C).

**Increased C3 staining and macrophage staining in kyphotic area of the spine of AxSpA mice**

IHC staining of the kyphotic area and of the bone growth area in mice with CAIA/AxSpA revealed an increased C3 deposition in the inter vertebral region (88%) and inter-vertebral disc (65%) (Fig. 2D) as compared with no C3 deposition in the control mice (Fig. 2E and F). These data suggest that the complement system is involved in the initiation and development of AxSpA.

IHC staining of the kyphotic area in mice CAIA and AxSpA also showed a significant (p<0.05) 75% increased macrophage infiltration, with localization to the inter-vertebral joint margins (Fig. 2G). Very little baseline macrophage staining was noticed in the mice with no CAIA and no AxSpA (Fig. 2H and I). These data clearly show that there is infiltration of the immune cells due to enthesitis in the kyphotic area.

At day 10, we also performed H&E staining of the spine of the kyphotic area and examined its interior surface (Fig. 3). We confirmed that there was an inflammation in the knee joints of
mice with arthritis compared with the control mice (Fig. 3A and B). Mice with CAIA/AxSpA demonstrated a significant hypertrophy of the cartilage as well as osseous damage of the inter-vertebral joints, as compared with no damage and no enthesitis in the untreated mice (Fig. 3C and D). There was multilayered pannus present similar to enthesitis on the side of inter vertebral disc (Fig. 3E) whereas no pannus was noticed in control mice as expected (Fig. 3F). Histological examination of the kyphotic area showed substantial bone damage only in the mice with arthritis and AxSpA (Fig. 3G) but not in control mice (Fig. 3H), which is an important characteristic of AxSpA. We could not confirm the fusion of the vertebrae in mice with CAIA/AxSpA-like phenotype (Fig. 3C).
In vivo localization of IRDye800 labeled anti-CII Abs in the arthritic joints and vertebrae of CAIA/AxSpA mice

We performed in vivo imaging using IRDye800 labeling to explore whether anti-CII Abs used to develop arthritis and AxSpA actually reached the joints, the kyphotic area of the spine and/or the vertebrae of the treated mice. In vivo imaging data show that IRDye800 labeled anti-CII Abs (Arthrogen-CIA®) were clearly visible (green color) not only in all the joints and fore paws ([Fig. 4A](#)) and hind paws ([Fig. 4B](#)) of mice, but also in the vertebrae ([Fig. 4C](#)) of mice with arthritis and AxSpA. In contrast, mIgG IRDye800 labeled, as control, was not localized similarly to the labeled anti-collagen Abs, indicating that mIgG cannot bind to the cartilage surface in the joints or on the vertebrae ([Fig. 4D](#)). Specifically IRDye800 labelled anti-CII mAbs, were also present in the kyphotic area of spine indicating that anti-CII mAbs bound on the surface of vertebrae in mice compared with the control mIgG. The spine lesion with heavily bound anti-CII Abs was clearly visible ([Fig. 4C](#)). Localization of the only labelled IRDye 800 anti-CII mAbs not mIgG in the kyphotic area showed that these Abs might be causing damage not only to the joints but also to the spine, causing AxSpA-like lesions.

**DISCUSSION**

We have serendipitously found a murine model of AxSpA-like lesions and sought to characterize some of the unique features of this model, using clinical and histopathological...
examinations. In this observational study, we first found that mice with arthritis consistently developed kyphosis. Second, mice with inflammatory arthritis not only showed joint damage but also to the spine during the development of AxSpA lesions. (A) IRDye800 labelled anti-CII mAbs localized in forelimbs (green color). (B) IRDye800 labelled anti-CII mAbs localized in hind limbs (green color). (C) Localization of the labelled anti-CII mAbs localized in spine (green color) indicating specifically anti-CII mAbs caused spine lesion similar to the AxSpA (white arrow). (D) IRDye800 labelled control mIgG not localized in the forelimbs (no green color). (E) IRDye800 labelled control mIgG not localized in hind limbs (no green color). (F) No localization of the IRDye800 labelled control mIgG in spine (no green color). Only fluorescence background is seen in mice injected with IRDye800 mIgG. One of the representative images of each from 2 independent, in vivo, experiments have been shown.

SpA can cause some of the vertebrae in the spine to fuse, therefore making the spine less flexible and resulting in a hunched-forward posture. As a consequence, mice with arthritis resulted in a hunched posture and difficulty in walking (Fig. 1A and C). Histopathology data show that there was enthesitis in the kyphosis in mice with inflammatory arthritis as well as bone damage (Fig. 3). Notably, in the enthesitis a multilayered pannus appeared to be destroying one side of the IVD in mice with arthritis in contrast to the mice with no CAIA. This is one of the most important pathological features of AxSpA (Fig. 3A and C) and

Figure 4. In vivo imaging of IRDye 800 labelled anti-CII mAbs and control mIgG at day 14. In vivo imaging of IRDye 800 labelled anti-CII mAbs actually not only reached joints but also to the spine during the development of AxSpA lesions. (A) IRDye800 labelled anti-CII mAbs localized in forelimbs (green color). (B) IRDye800 labelled anti-CII mAbs localized in hind limbs (green color). (C) Localization of the labelled anti-CII mAbs localized in spine (green color) indicating specifically anti-CII mAbs caused spine lesion similar to the AxSpA (white arrow). (D) IRDye800 labelled control mIgG not localized in the forelimbs (no green color). (E) IRDye800 labelled control mIgG not localized in hind limbs (no green color). (F) No localization of the IRDye800 labelled control mIgG in spine (no green color). Only fluorescence background is seen in mice injected with IRDye800 mIgG. One of the representative images of each from 2 independent, in vivo, experiments have been shown.
fusion of the vertebrae might be the late event in the pathogenesis of this disease. We also asked whether anti-collagen Abs deposited to regions of the spine where there is no initial inflammation. In that study, we found that IRDye800 labeled anti-collagen Abs consistently deposited in all joints and in the entire spine. We then examined all other areas of the spine without histopathology after autopsy, and we could not locate inflammation and/or lesions except in 3–4 vertebrae in arthritic mice. Surprisingly, these lesions on the spine were consistent from one cohort after another.

Although the role of HLA-B27 in AS is still be debated, one study has shown that HLA-B27 transgenic rats also showed more severe arthritis compared with WT mice in the CAIA model (27,35), indicating that 2 diseases can coexist. Nevertheless, the coexistence of RA and AS in the same patient is rare, but it has been reported (36).

Our data also suggest a role for complement in this model of AxSpA due to deposition of C3 in the IVD and surrounding areas of kyphosis (Fig. 2F). The complement system has been shown to be involved in earlier studies of Proteoglycan-induced AS in mice (23,37). Our data are also consistent with activation of complement C3 locally in the fused vertebrae area. However, which pathway of the complement system is involved in this mouse model of AxSpA is not clear. We do suggest that the AP of the complement system is involved because CAIA is dependent on the AP (32).

We do recognize limitations in this observation study. One of the limitations of our study is that we have not used an established scoring method to examine CDA for AxSpA, also we have not performed micro-computed tomography (microCT) (X-ray imaging characterization) of the kyphotic areas; for both areas, further validation is needed. Since microCT was not performed, therefore, we could not determine the presence of syndesmophytes around the vertebral rim area; which are an important characteristic components of spine pathology in AS. Histological characteristics such as hyperplasia, neo-angiogenesis, and infiltration of synovial sub lining with inflammatory cells between rheumatoid arthritis and SpA has been reported earlier (38,39). We have also not examined sacroiliac joints because sacroilitis is essential for axial lesions, and many studies mentioned above as limitations are planned the near future. Another limitation of our study is that we have used only the C57BL/6 mouse strain, but we think that AxSpA associated with CAIA may not be strain-specific, since the reactivity of anti-CII Abs is not strain specific. One of the most important questions is that whether or not C57BL/6 WT mice treated with K/BxN serum will develop AxSpA? We do not know, but it might be dependent on the effector function of specific autoantibodies involved. Spontaneous development of arthritis in K/BxN mouse model is dependent on pathogenic Abs to glucose-6-phosphate isomerase (GPI) protein and anti-GPI Abs binds to it (40). Interestingly anti-GPI Abs mAbs of the IgG1 isotype (41,42) induce arthritis in the joints bypassing T and B cells (41). Anti-collagen Abs we used to inducing CAIA are a mixture of 5 monoclonal Abs containing A2-10 (IgG2a), F10-21 (IgG2a), D8-6 (IgG2a), D1-2G (IgG2b), and D2-112 (IgG2b) without the IgG1 isotype. In addition to differences in targets recognized, different isotypes have different effector functions such as triggering FcγRs, Ab-dependent cell mediated cytotoxicity, and activating the complement system (43). We speculate that if anti-GPI Abs can bind to the cartilage or vertebral directly similar to IgG2a or IgG2b isotypes as we have shown, there is a possibility that serum transfer from K/BxN mice can induce AxSpA in C57BL/6 WT mice since the pathogenic effects of both Abs are identical.
Our data shows that mice injected with anti-CII Abs not only developed arthritis but also developed hunched pouch defects, from which we conclude that AxSpA in mice is potentially a by-product of inflammatory arthritis (44). We also showed that LPS by itself played no role in the co-development of AxSpA, since mice injected with LPS only developed a mild and transient arthritis or no arthritis (45); however, both anti-CII Abs and LPS injections were required to induce disease.

Regarding the pathophysiological mechanism to explain how an autoimmune disease such as RA can give rise to the initiation of another auto-inflammatory disease such as AxSpA, our data is very clear. We found that both diseases can be induced and coexist after the induction of anti-collagen Abs; furthermore, we observed that both spine lesions could be the by-product of underlying inflammatory arthritis. The correlation between chondrocyte proliferation in the kyphotic area of spine and CDA, i.e., arthritis phenotype was + 0.51 but not statistically significant. Furthermore, some studies demonstrate that there is an increase in the levels of anti-collagen Abs in AS patients (14,46) and their role in AxSpA initiation can’t be completely ruled out. Whether or not anti-CII Abs lead to the development of AxSpA is still an open question, and more studies are needed, but our current observation demonstrate that they not only induce arthritis but triggered spine lesions very similar to those in AxSpA. Interestingly anti-CII autoantibodies or anti-citrullinated protein Abs are also not a typical biomarker of AS compared with RA (47,48). However, autoantibodies to citrullinated type II collagen were detected in 78.5% of RA patients (49), as well as in 1 of 31 systemic lupus erythematosus patients and in 2 of 55 patients with osteoarthritis. Overall, many scholars agree that Abs with different auto-reactivities can be found in many autoimmune diseases, which may or may not be the direct cause of a specific disease, but they may play a role in the pathogenesis across autoimmune diseases.

In conclusion, none of the mouse models of AxSpA fully mirror human AxSpA but here we have found a new mouse model of AxSpA with many characteristics of enthesitis, IVD damage and chondrocyte proliferation as well as bone erosion along with inflammatory immune cell infiltration and complement activation. This mouse model of AxSpA might allow one to test complement based therapeutic drugs not only for RA but also for AxSpA.

ACKNOWLEDGEMENTS

Dr. Banda is grateful to faculty members and also an international scientists because after the discovery phase some or all of these data has been shared from time to time prior to publication for consultation with Dr. Robert I. Scheinman, PhD, University of Colorado Anschutz, Dr. Liron Kaplan, MD, PhD Denver Veterans Affairs Medical Center and Dr. Anne Troldborg, MD, PhD, Aarhus University Hospital, Denmark. The National Institutes of Health grant R01AR51749 to VMH (PI) and NKB (Co-I).

REFERENCES

1. Walsh J, Hunter T, Schroeder K, Sandoval D, Bolce R. Trends in diagnostic prevalence and treatment patterns of male and female ankylosing spondylitis patients in the United States, 2006-2016. BMC Rheumatol 2019;3:39.
2. Braun J, Bollow M, Remlinger G, Eggens U, Rudwaleit M, Distler A, Sieper J. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. *Arthritis Rheum* 1998;41:58-67. [PUBMED](https://doi.org/10.1002/art.1780410107) [CROSSREF](https://doi.org/10.1002/art.1780410107)

3. Tran TM, Dorris ML, Satumtira N, Richardson JA, Hammer RE, Shang I, Taurog JD. Additional human beta2-microglobulin curbs HLA-B27 misfolding and promotes arthritis and spondylitis without colitis in male HLA-B27-transgenic rats. *Arthritis Rheum* 2006;54:1317-1327. [PUBMED](https://doi.org/10.1002/art.21865) [CROSSREF](https://doi.org/10.1002/art.21865)

4. Baeten D, Breban M, Lories R, Schett G, Sieper J. Are spondylarthritides related but distinct conditions or a single disease with a heterogeneous phenotype? *Arthritis Rheum* 2013;65:12-20. [PUBMED](https://doi.org/10.1002/art.37371) [CROSSREF](https://doi.org/10.1002/art.37371)

5. Sherlock JP, Joyce-Shaikh B, Turner SP, Chao CC, Sathe M, Grein J, Gorman DM, McClanahan TK, Yearley JH, et al. IL-23 induces spondyloarthritis by acting on ROR-\(\gamma\)CD3^+CD4^-CD8^- entheseal resident T cells. *Nat Med* 2012;18:1069-1076. [PUBMED](https://doi.org/10.1038/nm.2582) [CROSSREF](https://doi.org/10.1038/nm.2582)

6. Liu CH, Raj S, Chen CH, Hung KH, Chou CT, Chen IH, Chien JT, Lin IY, Yang SY, Anguta T, et al. HLA-B27-mediated activation of TNAP phosphatase promotes pathogenic syndesmophyte formation in ankylosing spondylitis. *J Clin Invest* 2019;129:5357-5373. [PUBMED](https://doi.org/10.1172/JCI98924) [CROSSREF](https://doi.org/10.1172/JCI98924)

7. Colbert RA, DeLay ML, Klenk EI, Layh-Schmitt G. From HLA-B27 to spondyloarthritis: a journey through the ER. *Immunol Rev* 2010;233:181-202. [PUBMED](https://doi.org/10.1111/j.0161-2930.2009.00492.x) [CROSSREF](https://doi.org/10.1111/j.0161-2930.2009.00492.x)

8. Kingsbury DJ, Mear JP, Witte DP, Taurog JD, Roopenian DC, Colbert RA. Development of spontaneous arthritis in beta2-microglobulin-deficient mice without expression of HLA-B27: association with deficiency of endogenous major histocompatibility complex class I expression. *Arthritis Rheum* 2000;43:2290-2296. [PUBMED](https://doi.org/10.1002/art.1142) [CROSSREF](https://doi.org/10.1002/art.1142)

9. Liu Y, Liao X, Shi G. Autoantibodies in spondyloarthritis, focusing on anti-CD74 antibodies. *Front Immunol* 2019;10:5. [PUBMED](https://doi.org/10.3389/fimmu.2019.00005) [CROSSREF](https://doi.org/10.3389/fimmu.2019.00005)

10. Taams LS, Steel KJ, Srenathan U, Burns LA, Kirkham BW. IL-17 in the immunopathogenesis of spondyloarthritis. *Nat Rev Rheumatol* 2018;14:453-466. [PUBMED](https://doi.org/10.1038/s41584-018-0041-3) [CROSSREF](https://doi.org/10.1038/s41584-018-0041-3)

11. Curry R, Thoen I, Shelborne C, Gaudernack G, Messner R. Antibodies to and elevations of beta 2 microglobulin in the serum of ankylosing spondylitis patients. *Arthritis Rheum* 1982;25:375-380. [PUBMED](https://doi.org/10.1002/art.1780250404) [CROSSREF](https://doi.org/10.1002/art.1780250404)

12. Charrière G, Hartmann DJ, Vignon E, Ronzière MC, Herbage D, Ville G. Antibodies to types I, II, IX, and XI collagen in the serum of patients with rheumatic diseases. *Arthritis Rheum* 1988;31:325-332. [PUBMED](https://doi.org/10.1002/art.1780310305) [CROSSREF](https://doi.org/10.1002/art.1780310305)

13. Hušáková M, Bay-Jensen AC, Forejtová Š, Zegzulková K, Tomčík M, Gregová M, Bubová K, Hořínková J, Gatterová J, Pavelka K, et al. Metabolites of type I, II, III, and IV collagen may serve as markers of disease activity in axial spondyloarthritis. *Sci Rep* 2019;9:11218. [PUBMED](https://doi.org/10.1038/s41598-018-38746-3) [CROSSREF](https://doi.org/10.1038/s41598-018-38746-3)

14. Tani Y, Sato H, Tanaka N, Mori K, Doida Y, Hukuda S. Serum IgA1 and IgA2 subclass antibodies against collagens in patients with ankylosing spondylitis. *Scand J Rheumatol* 1997;26:380-382. [PUBMED](https://doi.org/10.3109/03009749708963477) [CROSSREF](https://doi.org/10.3109/03009749708963477)

15. Holers VM, Banda NK. Complement in the initiation and evolution of rheumatoid arthritis. *Front Immunol* 2018;9:1057. [PUBMED](https://doi.org/10.3389/fimmu.2018.00105) [CROSSREF](https://doi.org/10.3389/fimmu.2018.00105)

16. Noris M, Remuzzi G. Overview of complement activation and regulation. *Semin Nephrol* 2013;33:479-492. [PUBMED](https://doi.org/10.1053/j.semnephrol.2013.07.003) [CROSSREF](https://doi.org/10.1053/j.semnephrol.2013.07.003)

17. Banda NK, Takahashi K, Wood AK, Holers VM, Arend WP. Pathogenic complement activation in collagen antibody-induced arthritis in mice requires amplification by the alternative pathway. *J Immunol* 2007;179:4101-4109. [PUBMED](https://doi.org/10.4049/jimmunol.179.8.4101) [CROSSREF](https://doi.org/10.4049/jimmunol.179.8.4101)

18. Lofchý LA, Vu VP, Banda NK, Ramírez JR, Smith WJ, Gifford G, Gaikwad H, Scheinman RI, Simberg D. Evaluation of targeting efficiency of joints with anticollagen II antibodies. *Mol Pharm* 2019;16:2445-2451. [PUBMED](https://doi.org/10.1021/acs.molpharmaceut.9b00166) [CROSSREF](https://doi.org/10.1021/acs.molpharmaceut.9b00166)

19. Abdelaziz MM, Gamal RM, Ismail NM, Lasy RA, Hetta HF. Diagnostic value of anti-CD74 antibodies in early and late axial spondyloarthritis and its relationship to disease activity. *Rheumatology (Oxford)* 2021;60:263-268. [PUBMED](https://doi.org/10.1093/rheumatology/keaa259) [CROSSREF](https://doi.org/10.1093/rheumatology/keaa259)
20. Kinsella TD, Espinoza L, Vasey FB. Serum complement and immunoglobulin levels in sporadic and familial ankylosing spondylitis. *J Rheumatol* 1975;2:308-313.

PubMed

21. Krauledat PB, Krapf FE, Manger B, Kalden JR. Evaluation of plasma C3d and immune complex determinations in the assessment of disease activity of patients with rheumatoid arthritis, systemic lupus erythematosus, and spondylitis ancylopoetica. *Rheumatol Int* 1985;5:97-101.

PubMed | Crossref

22. Panayi GS, Slaney J, Williams BD. Circulating immune complexes in patients with ankylosing spondylitis. *Ann Rheum Dis* 1980;39:445-448.

PubMed | Crossref

23. Yang C, Ding P, Wang Q, Zhang L, Zhang X, Zhao J, Xu E, Wang N, Chen J, Yang G, et al. Inhibition of complement retards ankylosing spondylitis progression. *Sci Rep* 2016;6:34643.

PubMed | Crossref

24. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, DE Groot PG, Koike T, Meroni PL, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). *J Thromb Haemost* 2006;4:295-306.

PubMed | Crossref

25. Bárdos T, Szabó Z, Czipri M, Vermes C, Tunyogi-Csapó M, Urban RM, Mikecz K, Glant TT. A longitudinal study on an autoimmune murine model of ankylosing spondylitis. *Ann Rheum Dis* 2005;64:981-987.

PubMed | Crossref

26. Glant TT, Mikecz K, Arzoumanian A, Poole AR. Proteoglycan-induced arthritis in BALB/c mice. Clinical features and histopathology. *Arthritis Rheum* 1987;30:201-212.

PubMed | Crossref

27. Taurog JD, Maika SD, Satumtira N, Dorris ML, McLean IL, Yanagisawa H, Sayad A, Stagg AJ, Fox GM, Lê O’Brien A, et al. Inflammatory disease in HLA-B27 transgenic rats. *Immunol Rev* 1999;169:209-223.

PubMed | Crossref

28. Weinreich S, Eulderink F, Capkova J, Pla M, Gaede K, Heesemann J, van Alphen L, Zurcher C, Hoebe-Hewryk B, Kievits F, et al. HLA-B27 as a relative risk factor in ankylosing enthesopathy in transgenic mice. *Hum Immunol* 1995;42:103-115.

PubMed | Crossref

29. Khare SD, Hansen J, Luthra HS, David CS. HLA-B27 heavy chains contribute to spontaneous inflammatory disease in B27/human beta2-microglobulin (beta2m) double transgenic mice with disrupted mouse beta2m. *J Clin Invest* 1996;98:2746-2755.

PubMed | Crossref

30. Ruutu M, Thomas G, Steck R, Degli-Esposti MA, Zinkernagel MS, Alexander K, Velasco J, Strutton G, Tran A, Benham H, et al. β-glucan triggers spondylarthritis and Crohn's disease-like ileitis in SKG mice. *Arthritis Rheum* 2012;64:2211-2222.

PubMed | Crossref

31. Taylor SR, Turner CM, Elliott JI, McDaid J, Hewitt R, Smith J, Pickering MC, Whitehouse DL, Cook HT, Burnstock G, et al. P2X7 deficiency attenuates renal injury in experimental glomerulonephritis. *J Am Soc Nephrol* 2009;20:1275-1281.

PubMed | Crossref

32. Banda NK, Thurman JM, Kraus D, Wood A, Carroll MC, Arend WP, Holers VM. Alternative complement pathway activation is essential for inflammation and joint destruction in the passive transfer model of collagen-induced arthritis. *J Immunol* 2006;177:1904-1912.

PubMed | Crossref

33. Tseng HW, Pitt ME, Glant TT, McRae AF, Kenna TJ, Brown MA, Pettit AR, Thomas GP. Inflammation-driven bone formation in a mouse model of ankylosing spondylitis: sequential but not parallel processes. *Arthritis Res Ther* 2016;18:35.

PubMed | Crossref

34. Banda NK, Hyatt S, Antonioli AH, White JT, Glogowska M, Takahashi K, Merkel TJ, Stahl GL, Mueller-Ortiz S, Wetsel R, et al. Role of C3a receptors, C5a receptors, and complement protein C6 deficiency in collagen antibody-induced arthritis in mice. *J Immunol* 2012;188:1460-1478.

PubMed | Crossref

35. Neerinckx B, Kollnberger S, Shaw J, Lories R. No evidence for a direct role of HLA-B27 in pathological bone formation in axial SpA. *RMD Open* 2017;3:e000451.

PubMed | Crossref

36. Barczyńska TA, Węgierska M, Zuchowski P, Dura M, Zalewska J, Waszczak M, Jeka S. Coexistence of rheumatoid arthritis and ankylosing spondylitis. *Reumatologia* 2015;53:279-285.

PubMed | Crossref

https://immunenetwork.org

https://doi.org/10.4110/in.2021.21.e45

12/13
37. Brinch L, Vinje O, Teisberg P, Mellbye OJ, Aakesson I. The in-vivo metabolism of C3 in ankylosing spondylitis. *Ann Rheum Dis* 1982;41:86-89.

PUBMED | CROSSREF

38. Baeten D, Kruithof E, De Rycke L, Boots AM, Mielants H, Veys EM, De Keyser F. Infiltration of the synovial membrane with macrophage subsets and polymorphonuclear cells reflects global disease activity in spondyloarthropathy. *Arthritis Res Ther* 2005;7:R359-R369.

PUBMED | CROSSREF

39. Kruithof E, Baeten D, De Rycke L, Vandooren B, Foell D, Roth J, Cañete JD, Boots AM, Veys EM, De Keyser F. Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthritis more than it does rheumatoid arthritis. *Arthritis Res Ther* 2005;7:R569-R580.

PUBMED | CROSSREF

40. Ji H, Ohmura K, Mahmoud U, Lee DM, Hofhuis FM, Boackle SA, Takahashi K, Holers VM, Walport M, Gerard C, et al. Arthritis critically dependent on innate immune system players. *Immunity* 2002;16:157-168.

PUBMED | CROSSREF

41. Korganow AS, Ji H, Mangialaio S, Duchatelle V, Pelanda R, Martin T, Degott C, Kikutani H, Rajewsky K, Pasquali JL, et al. From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. *Immunity* 1999;10:451-461.

PUBMED | CROSSREF

42. Maccioni M, Zeder-Lutz G, Huang H, Ebel C, Gerber P, Hergueux J, Marchal P, Duchatelle V, Degott C, van Regenmortel M, et al. Arthritogenic monoclonal antibodies from K/BxN mice. *J Exp Med* 2002;195:1071-1077.

PUBMED | CROSSREF

43. Vidarsson G, Dekkers G, Rispeus T. IgG subclasses and allotypes: from structure to effector functions. *Front Immunol* 2014;5:520.

PUBMED | CROSSREF

44. Banda NK. An accidental discovery of a new potential mouse model of the axial spondyloarthritis. *J Immunol* 2019;202:133.

PUBMED | CROSSREF

45. Banda NK, Mehta G, Kjaer TR, Takahashi M, Schaack J, Morrison TE, Thiel S, Arend WP, Holers VM. Essential role for the lectin pathway in collagen antibody-induced arthritis revealed through use of adenovirus programming complement inhibitor MAP44 expression. *J Immunol* 2014;193:2455-2468.

PUBMED | CROSSREF

46. Tani Y, Sato H, Hukuda S. Autoantibodies to collagens in Japanese patients with ankylosing spondylitis. *Clin Exp Rheumatol* 1997;15:295-297.

PUBMED | CROSSREF

47. von Mühlen CA, Tan EM. Autoantibodies in the diagnosis of systemic rheumatic diseases. *Semin Arthritis Rheum* 1995;24:323-358.

PUBMED | CROSSREF

48. Mohan C, Assassi S. Biomarkers in rheumatic diseases: how can they facilitate diagnosis and assessment of disease activity? *BMJ* 2015;351:h5079.

PUBMED | CROSSREF

49. Yoshida M, Tsuji M, Kurosaka D, Kurosaka D, Yasuda J, Ito Y, Nishizawa T, Yamada A. Autoimmunity to citrullinated type II collagen in rheumatoid arthritis. *Mod Rheumatol* 2006;16:276-281.

PUBMED | CROSSREF